Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NRIX

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRIX
DateTimeSourceHeadlineSymbolCompany
07/05/202421:00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
17/04/202408:21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
12/04/202413:38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
12/04/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202421:00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
10/04/202403:15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
09/04/202421:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6NASDAQ:NRIXNurix Therapeutics Inc
03/04/202422:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
02/04/202422:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesNASDAQ:NRIXNurix Therapeutics Inc
25/03/202422:00GlobeNewswire Inc.Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)NASDAQ:NRIXNurix Therapeutics Inc
21/03/202400:40GlobeNewswire Inc.Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingNASDAQ:NRIXNurix Therapeutics Inc
11/03/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
11/03/202422:00GlobeNewswire Inc.Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNASDAQ:NRIXNurix Therapeutics Inc
07/03/202408:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
06/03/202408:30GlobeNewswire Inc.Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
17/02/202411:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
17/02/202408:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
16/02/202408:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NRIXNurix Therapeutics Inc
16/02/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
16/02/202408:00GlobeNewswire Inc.Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
15/02/202423:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202423:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202423:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202400:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRIXNurix Therapeutics Inc
02/02/202408:01GlobeNewswire Inc.Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderNASDAQ:NRIXNurix Therapeutics Inc
31/01/202410:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
31/01/202410:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
31/01/202410:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
30/01/202408:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NRIXNurix Therapeutics Inc
17/01/202408:48Dow Jones NewsNurix Therapeutics Gets FDA Fast-Track Designation for NX-5948NASDAQ:NRIXNurix Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NRIX

Your Recent History

Delayed Upgrade Clock